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Abstract
Background: Treatment with nab-paclitaxel plus gemcitabine increases survival in patients with metastatic
pancreatic cancer. However, the assessment of treatment efficacy and safety in non-selected patients in a real-life
setting may provide useful information to support decision-making processes in routine practice.
Methods: Retrospective, multicenter study including patients with metastatic pancreatic cancer, who started first-
line treatment with nab-paclitaxel plus gemcitabine between December 2013 and June 2015 according to routine
clinical practice. In addition to describing the treatment pattern, overall survival (OS) and progression-free survival
(PFS) were assessed for the total sample and the exploratory subgroups based on the treatment and patients’
clinical characteristics.
Results: All 210 eligible patients had a median age of 65.0 years (range 37–81). Metastatic pancreatic
adenocarcinoma was recurrent in 46 (21.9%) patients and de novo in 164 (78.1%); 38 (18%) patients had a biliary
stent. At baseline, 33 (18.1%) patients had an ECOG performance status ≥2. Patients received a median of four
cycles of treatment (range 1–21), with a median duration of 3.5 months; 137 (65.2%) patients had a dose reduction
of nab-paclitaxel and/or gemcitabine during treatment, and 33 (17.2%) discontinued treatment due to toxicity.
Relative dose intensity (RDI) for nab-paclitaxel, gemcitabine, and the combined treatment was 66.7%. Median OS
was 7.2 months (95% CI 6.0–8.5), and median PFS was 5.0 months (95% CI 4.3–5.9); 50 patients achieved either a
partial or complete response (ORR 24.6%). OS was influenced by baseline ECOG PS, NLR and CA 19.9, but not by
age ≥ 70 years and/or the presence of hepatobiliary stent or RDI < 85%. All included variables, computed as
dichotomous, showed a significant contribution to the Cox regression model to build a nomogram for predicting
survival in these patients: baseline ECOG 0–1 vs. 2–3 (p = 0.030), baseline NLR > 3 vs. ≤ 3 (p = 0.043), and baseline
CA 19.9 > 37 U/mL vs. ≤37 U/mL (p = 0.004).
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Conclusions: Nab-Paclitaxel plus gemcitabine remain effective in a real-life setting, despite the high burden of
dose reductions and poorer performance of these patients. A nomogram to predict survival using baseline ECOG
performance status, NLR and CA 19.9 is proposed.
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Background
Pancreatic adenocarcinoma, the most common form of
pancreatic cancer, is currently the fourth cause of
cancer-related mortality in Europe and the United States,
with a 5-year survival rate in the range of 6–10% [1–4].
This has been attributed, among other causes, to the
premature vascular, lymphatic and perineural spread of
these tumors, which makes that 85% of patients present
disseminated disease at diagnosis. Only between 15 and
20% of tumors are resectable and, within these, 50 to 86%
will experience local failure despite curative resection,
with a resulting 5-year survival rate of 10–20% [5].
Gemcitabine has been the standard first-line treat-
ment for advanced pancreatic cancer for 15 years, and
it is associated with median overall survivals (OS)
ranging from 5.6 to 6.8 months [6]. Its combination
with a wide range of other agents such as capecita-
bine, oxaliplatin, cisplatin, irinotecan, and erlotinib
has unfortunately shown little impact on survival in
this population [6, 7]. Nonetheless, two combination
regimens, FOLFIRINOX (folinic acid, fluorouracil, iri-
notecan, oxaliplatin) and more recently, nab-paclitaxel
plus gemcitabine, have been associated with a median
OS of 11.1 months and 8.5 months in the ACCORD4/
PRODIGE11 and MPACT phase III clinical trials, re-
spectively [8, 9]. These encouraging results have set a
new standard and international guidelines now recom-
mend FOLFIRINOX and nab-paclitaxel plus gemcitabine
as first-line treatments in patients with metastatic pancre-
atic cancer [10, 11].
A questionnaire-based study showed that clinicians are
likely to adhere to the selection criteria of these trials,
being the patient’s performance status one of the most
influential factors in the decision-making process in the
real-life setting [12]. As randomized trials have strict
selection criteria, particularly regarding performance sta-
tus and age [8, 9], reported data might not capture the
scenario faced in the real-life setting, with non-selected
patients. A prospective registry-based study showed that
fewer than half of the patients treated in routine clinical
practice would have been eligible for the PRODIGE or
MPACT trials and that meeting the eligibility criteria for
either trial is associated with longer survival [13].
Clinicians are increasingly interested in obtaining
real-life data from daily practice, which completes the
clinical picture of randomized trials. As such, observa-
tional trials can provide useful information for clinicians
to support decision-making processes in their routine
practice, especially when treating patient groups under-
represented in clinical trials, as are elderly patients and
those with poorer performance status [14, 15]. In line
with this unmet need, Ellenrieder et al. highlighted the
importance of real-life data regarding first-line regimens
in metastatic pancreatic cancer to select the most
suitable treatment for each patient [7]. The aim of
the ANICE study was to assess the effectiveness and
tolerability of gemcitabine and nab-paclitaxel as
first-line therapy for metastatic pancreatic cancer in a
real-life setting.
Methods
Study design and patients
The ANICE trial was an observational, retrospective,
multicenter study focused on patients with metastatic
pancreatic adenocarcinoma (recurrent or de novo)
treated according to routine clinical practice at 20
Spanish hospitals between December 2013 and June
2015. All adult patients (≥ 18 years) with measurable
metastatic disease at baseline in at least one dimension
(per Response Evaluation Criteria in Solid Tumors
[RECIST], version 1.1, [16]) who received at least one
dose of nab-paclitaxel (Abraxane®, Celgene Europe
Limited) plus gemcitabine as first-line chemotherapy
were included. Data were obtained from clinical medical
records with a cut-off date of 16 March 2017. All
patients provided written informed consent. The study
protocol was approved by the local independent ethics
committee, and was conducted in accordance with the
Spanish personal data protection law (LOPD 15/1999).
Variables and endpoints
Variables collected from the patient’s medical records
included demographic data (sex and age), clinical data,
characteristics of the metastatic disease and treatment.
Among the registered clinical and disease characteristics
were performance status (PS) (ECOG and Karnofsky
scales), relevant comorbidities, initial diagnosis, number
and localization of metastases, time between diagnosis
of the primary tumor and recurrence, presence of a
hepatobiliary stent, serum bilirubin, neutrophil/lymphocyte
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ratio (NLR), and CA 19.9 antigen levels. Treatment charac-
teristics included concomitant treatments, relative dose
intensity (RDI) for nab-paclitaxel plus gemcitabine (i.e., per
the summary of product characteristics), treatment
duration, cause of treatment discontinuation, number of
cycles, and dose reductions and interruptions. Decisions
regarding the initial dose and subsequent dose reductions
were made at physicians’ discretion, based on patient’s PS
and toxicity, and following the routine practice of each
participating sit.
The primary objective was to describe the treatment
pattern in terms of extent of exposure and reductions of
treatment with nab-paclitaxel plus gemcitabine in
real-life clinical practice. Secondary objectives included
objective response rate (ORR), progression-free survival
(PFS) defined as the time from the start of treatment to
disease progression or all-cause death, overall survival
(OS) defined as the time from the start of treatment to
death from any cause, and the 12-month survival rate
defined as the percentage of patients alive at 12 months
after starting treatment. Safety was assessed in terms of
adverse events (AE), coded according to the preferred
term of the Medical Dictionary for Regulatory Activities
(MedDRA), and graded according to the National Cancer
Institute-Common Toxicity Criteria (version 4.0) [17].
Statistical analyses
Given the descriptive nature of the statistical analyses,
the sample size was calculated based on the confidence
interval (CI) of the 12-month survival rate. Considering
the 12-month survival rate previously reported by
Goldstein et al. [18], and assuming that nearly 20% of
patients present with recurrent metastatic cancer, a
sample of 225 patients was deemed necessary to esti-
mate a 12-month survival rate of 30% with a ± 6% preci-
sion and a 95% CI.
Categorical variables were summarized as frequencies
and percentages, and quantitative variables as the mean
and standard deviation (SD) and/or median and inter-
quartile range (IQR). The quantitative variables NLR
and CA 19.9 were transformed into dichotomous
variables with the cut-offs values of 3 and 37 U/mL, re-
spectively. Categorical values were compared using the
Fisher’s exact test or the chi-square test when the
requirements for a Fisher’s exact test could not be
assumed. Quantitative values were compared using the
T-test, ANOVA test, and their non-parametric counter-
parts, the Wilcoxon and Kruskal-Wallis tests. OS and
PFS curves were plotted using the Kaplan-Meier esti-
mate, and compared according to selected parameters
using the Log-rank test and the Cox regression model.
The significance threshold for all bivariate analyses was
set at a two-sided α = 0.05. All factors showing a signifi-
cant influence on OS in the bivariate analysis were
included in a Cox regression model as dichotomous
variables to build a nomogram for predicting OS in
real-life practice. The obtained hazard ratios (HR) were
used to associate each variable with a survival score. In
addition to the predicted survival, a probability for 3-,
6-, 12, and 18-month survival was estimated. Based on
the range of final scores resulting from the possible
combinations of variables, low-, medium-, and
high-risk groups were defined. All analyses were per-




Of the 216 patients recruited, 6 were excluded for one
or more of the following reasons: not initiating com-
bined treatment with gemcitabine plus nab-paclitaxel
(n = 4), absence of measurable disease at baseline per
RECIST (n = 2), and being enrolled in a clinical trial
(n = 1). Table 1 summarizes the demographic and clinical
characteristics of study patients. The 210 eligible pa-
tients had a median age of 65.0 years (range 37–81).
Metastatic pancreatic adenocarcinoma was recurrent in
46 (21.9%) patients and de novo in 164 (78.1%). For
patients with recurrent metastatic disease, the primary
tumor was resectable in 38 cases (82.6%), borderline in
3 (6.5%), and locally advanced unresectable in 5 (10.9%),
and median time to recurrence was 11.0months.
Assessment of eligibility for the MPACT and ACCORD4/
PRODIGE11 trials could be assessed in 78 (37.1%) and
172 (81.9%) patients, respectively, with 37 meeting
the criteria for entering the MPACT trial and 109 the
ACCORD4/PRODIGE11 trial.
Treatment characteristics and outcome
Table 2 summarizes treatment characteristics. Median
time from diagnosis to treatment start was 28 days.
Patients received a median of 4 cycles (range 1–21) of
treatment, with a median treatment duration of 3.5
months. Sixty-eight patients (32%) started treatment
with dose reduction for either nab-paclitaxel, gemci-
tabine or both drugs. Table 3 summarizes the base-
line characteristics of the 68 patients with dose
reduction and treatment start. The median RDIs were
66.7% for nab-paclitaxel, gemcitabine, and the com-
bined treatment. Overall, 137 patients (65.2%) had a
dose reduction in nab-paclitaxel and/or gemcitabine
during treatment. Thirty-four (17%) patients received
≤30 days of treatment, mainly due to toxicity (n = 11)
or disease progression (n = 10). There were no signifi-
cant differences between patients receiving ≤30 days
of treatment and those receiving > 30 days in terms
of baseline clinical characteristics including perform-
ance status, the presence of a hepatobiliary stent,
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NLR, CA 19.9 and bilirubin levels, or weight loss of
more than 10%.
At the time of data collection, median follow-up
was 7.2 months (IQR 3.5–13.3). A total of 193 pa-
tients (91.9%) had died, with a 12-month survival
rate of 30.1%. Median OS was 7.2 months (95% CI
6.0–8.5), and median PFS 5.0 months (95%CI 4.3–
5.9). Among 203 patients eligible for response, 50
patients achieved either a partial or complete re-
sponse (ORR 24.6%), and 72 patients (35.5%) a
stable disease. Ninety-seven patients (46.9%) received
further treatment lines, most of whom (n = 63,
64.9%) had one or two lines of treatment (n = 25,
25.8%).
Table 1 Demographic and clinical characteristics of study patients
Numbera Overall Recurrent De novo
Demographic characteristics
Age, n (%) 210
< 65 years 99 (47.1%) 22 (47.8%) 77 (47.0%)
65–69 years 58 (27.6%) 8 (17.4%) 50 (30.5%)
≥ 70 years 53 (25.2%) 16 (34.8%) 37 (22.6%)
Sex, n (%) 210
Males 127 (60.5) 33 (71.7) 94 (57.3)
Females 83 (39.5) 13 (28.3) 70 (42.7)
Clinical characteristics
Weight loss > 10%, n (%) 208 81 (38.9) 9 (20.5) 72 (43.9)
ECOG PS, n (%) 182
0–1 149 (81.9) 28 (77.8) 121 (82.9)
2–3 33 (18.1) 8 (22.2) 25 (17.1)
Karnofsky PS, n (%) 55
< 70 3 (5.5) – 3 (6.8)
70–80 33 (60.0) 7 (63.6%) 26 (59.1%)
90–100 19 (34.5) 4 (36.4%) 15 (34.1%)
Common comorbidities, n (%) 210
Hypertension 56 (26.7) 8 (17.4) 48 (29.3)
Diabetes 26 (12.4) 4 (8.7) 22 (13.4)
Dyslipemia 29 (13.8) 6 (13.0) 22 (13.4)
Hepatobiliary stent, n (%) 209 38 (18.2) 3 (6.5) 35 (21.5)
Platelet count, median (IR) 178 231.0 (172.0, 318.0) 207.0 (170.0, 303.0) 237.0 (181.0, 318.0)
Bilirubin (mg/dL), median (IR) 175 0.70 (0.50, 1.00) 0.57 (0.50, 0.80) 0.79 (0.50, 1.10)
NLR, n (%) 170
> 3 91 (53.5) 18 (52.9) 73 (53.7)
≤ 3 79 (46.5) 16 (47.1) 63 (46.3)
CA 19.9, n (%) 173
> 37 U/mL 142 (82.1) 32 (82.1) 110 (82.1)
≤ 37 U/mL 31 (17.9) 7 (17.9) 24 (17.9)
Number of metastatic sites, n (%) 210
1–3 205 (97.6) 46 (100.0) 159 (97.0)
> 3 5 (2.4) 5 (3.0)
Concommitant treatment, n (%) 210
Analgesics 76 (36.2) 12 (26.1) 63 (38.4)
Corticosteroids 25 (11.9) 4 (8.7) 20 (12.2)
IR Interquartile range (percentile 25, percentile 75)
anumber of evaluable patients (no-missing)
Fernández et al. BMC Cancer         (2018) 18:1185 Page 4 of 11
Safety
Grade ≥ 3 treatment-related AEs were reported in 78
patients (37.1%), the most common being neutro-
penia, thrombocytopenia, and fatigue (Table 4). One
treatment-related event of paralytic ileus led to treat-
ment interruption and death.
Patients aged < 70 years received a median of 5 cycles of
combined treatment and patients aged ≥70 years received
a median of 3. Of 53 elderly patients (i.e., aged ≥70 years),
38 (71.7%) experienced at least one treatment-related AE,
compared to 78.1% in the overall population, with similar
profile of grade ≥ 3 events (Table 4). No significant differ-
ences were found in the frequency of treatment-related
AEs of grade 3 or higher between patients aged ≥70 years
and < 70 (39.6% vs. 36.3%; p = 0.789).
Prognostic factors
Analysis of the influence of baseline characteristics on
survival showed that only ECOG, NLR, and CA 19.9 sig-
nificantly influenced OS, PFS (Fig. 1), and/or 12-month
survival. Baseline CA 19.9 had a significant influence on
the three analyzed outcomes: patients with CA 19.9 ≤ 37
U/mL had longer OS (p = 0.004) (Fig. 1e), PFS (p =
0.011) (Fig. 1f ), and a higher 12-month survival rate
(45.2% vs. 24.8%; p = 0.030). On the other hand, patients
with baseline NLR ≤ 3 had longer OS (p = 0.024) (Fig. 1c)
and a higher 12-month survival rate than those with
NLR > 3 (38% vs. 23.3%; p = 0.045) but showed similar
PFS (Fig. 1d). Patients with a baseline ECOG PS of 0 or
1 had longer OS than those with an ECOG PS of 2 or 3
(p = 0.018) (Fig. 1a), although this trend was not ob-
served in PFS (Fig. 1b). Likewise, the 12-month survival
for patients with ECOG PS 0 or 1 and 2 or 3 was 31.1
and 21.2%, respectively (p = 0.297). Patients with stable
ECOG (n = 68) or ECOG improvement (n = 22) during
the first three treatment cycles had longer OS than
those with a worsening ECOG (n = 19), with a median
OS of 12.9 months (95% CI 6.7–15.4), 10.6 months
(95% CI 8.1–13.3), and 7.1 months (95% CI 4.7–9.2)
Table 2 Treatment characteristics
No. (%)
Started treatment with dose reduction, n (%)
Only gemcitabine 1 (0.5)
Only nab-Paclitaxel 41 (19.5)
Both 26 (12.4)
Dose reduction during treatment, n (%)
Nab-Paclitaxel 91 (43.3)
Gemcitabine 75 (35.7)
Either of the two drugs 96 (45.7)
Received ≤30 days of treatment, n (%) 34 (16.5)




Patient’s request 7 (3.6)
aA patient could have more than one reason for treatment discontinuation
Table 3 Demographic and clinical characteristics of patients
who started treatment with dose reduction
Demographic characteristics
Age, n (%) (n = 68)
< 65 years 33 (48.5%)
65–79 years 14 (20.6%)
≥ 70 years 21 (30.9%)




Weight loss > 10%, n (%) (n = 66) 18 (27.3%)
ECOG PS, n (%) (n = 62)
0–1 46 (74.2%)
2-Mar 16 (25.8%)








Hepatobiliary stent, n (%) (n = 68) 10 (14.7%)
Platelet count, median (IR) (n = 57) 252.0 (172.0, 339.0)
Bilirubin (mg/dL), median (IR) (n = 58) 0.70 (0.51, 1.10)
NLR, n (%) (n = 55)
> 3 29 (52.7%)
≤ 3 26 (47.3%)
CA 19.9, n (%) (n = 62)
> 35 52 (83.9%)
≤ 35 10 (16.1%)
Number of metastatic sites, n (%) (n = 68)
1–3 67 (98.5%)
> 3 1 (1.5%)
Concommitant treatment, n (%) (n = 68)
Analgesics 22 (32.4%)
Corticosteroids 9 (13.2%)
IR Interquartile range (percentile 25, percentile 75)
anumber of evaluable patients (no-missing)
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for ECOG improvement, stable, and worsening, re-
spectively (p = 0.020).
Neither age ≥ 70 years, the presence of an hepatobiliary
stent, nor an RDI of gemcitabine plus nab-paclitaxel
< 85% showed a significant influence on median PFS and
OS at 12 months (Fig. 2). The 12-month survival rate
was 28.3 and 30.8% for patients aged ≥70 and < 70 years,
respectively (p = 0.863); 36.8 and 28.8% for patients with
and without hepatobiliary stent, respectively (p = 0.335);
and 28.0 and 31.5% for patients with RDI of the com-
bined treatment ≥85 and < 85%, respectively (p = 0.645).
Factors significantly influencing OS (ECOG PS, NLR,
and CA 19.9) were used to build a nomogram to predict
survival of patients with pancreatic adenocarcinoma
treated in the real-life setting (Fig. 3a). All included vari-
ables, computed as dichotomous, showed a significant
contribution to the Cox regression model: baseline
ECOG PS 0 or 1 vs 2 or 3 (p = 0.030), baseline NLR > 3
vs ≤ 3 (p = 0.043), and baseline CA 19.9 > 37 U/mL vs
≤ 37 U/mL (p = 0.004) (Fig. 3a). Based on the scale ob-
tained with the nomogram, three risk groups were de-
fined: low-risk group (n = 21, 15.1%), medium-risk group
(n = 93, 66.9%), and high-risk group (n = 25, 18.0%).
Figure 3b shows the survival curves (Kaplan-Meier
estimates for these groups).
Discussion
In this observational retrospective study including all
the patients with metastatic pancreatic cancer treated at
the participating centers with first-line nab-paclitaxel
plus gemcitabine in a real-life setting, 25% of patients
were aged 70 years or more and 18% had a baseline
ECOG score of 2 or 3. Furthermore, 32% of patients
started combined treatment with a dose reduction of
nab-paclitaxel, and 17% of patients discontinued
treatment within 30 days of treatment, 33% of them due
toxicity. Despite the poor baseline characteristics in our
cohort, median OS and PFS were of 7.2 months (95% CI
6.0, 8.5) and 5.0 months (4.3, 5.9), respectively, indicating
that this combination is effective in the real-life setting.
OS was influenced by the baseline ECOG PS, NLR, and
CA 19.9, but not by age ≥ 70 years, the presence of
hepatobiliary stent or RDI < 85%.
Randomized controlled trials investigating therapies
for metastatic pancreatic cancer have restrictive selection
criteria, particularly regarding the patient’s age and per-
formance status [8, 9]. In the case of the pivotal study of
the combined treatment (MPACT trial), a Karnofsky
index of 70 or more was required [9]. In Spain the
preferred scale to assess the performance status in most
centers is the ECOG score, thus, in our study, the
Karnofsky index could only be assessed in a limited
number of patients. However, although the Karnofsky
index and the ECOG score lack a linear relationship for
direct comparisons between study populations, the fact
that 18% of patients had ECOG ≥2 (roughly ≥70 in the
Karnofsky index) indicates a trend towards a poorer
average performance status in our study population than
those in the pivotal MPACT trial. In the case of the
ACCORD4/PRODIGE11 study, recruitment was
limited to patients under 76 years with ECOG per-
formance status ≤1; [8] based on these criteria alone,
nearly 40% of our study patients would have been
excluded. In addition to the patients’ baseline charac-
teristics, treatment patterns in real-life practice often
differ from those used in pivotal trials. In our study,
66.2% of patients had a dose reduction in either
nab-paclitaxel and/or gemcitabine. Overall, the me-
dian RDI was 67% for both nab-paclitaxel and gemci-
tabine, which is well below those reported in the
MPACT trial (81 and 75% for nab-paclitaxel and
gemcitabine, respectively). Thus, the demographic,
clinical and treatment characteristics of this large co-
hort of real-life patients underscore fundamental dif-
ferences between RCTs and routine practice settings.
Despite the inclusion of elderly patients, the trend to-
wards a poorer performance status, and adjusted treat-
ment schedule in our study, our results confirmed the
effectiveness of combined treatment with gemcitabine
plus nab-paclitaxel in the real-life setting. The estimated
median OS (7.2 months) was slightly lower than that ob-
served in the MPACT trial (8.5 months) and those re-
ported by Giordano et al. (11 months), Lo Re et al. (9.2
months), and De Vita et al. (10 months) in three series
of 118, 37, and 41 real-life patients, respectively [19–21].
Likewise, the median PFS of our cohort (5.0 months)
was comparable to that reported in the MPACT trial
(5.5 months), but lower than that reported by Giordano
et al. (7 months), Lo Re et al. (6.2 months), and of
Table 4 Common treatment-related adverse events (> 1% of








Neutropenia 38 (18.1) 33 (21.0) 5 (9.4)
Thrombocytopenia 13 (6.2) 9 (5.7) 4 (7.5)
Anemia 7 (3.3) 2 (1.3) 5 (9.4)
Febrile neutropenia 4 (1.9) 2 (1.3) 2 (3.8)
Non-hematological toxicities
Fatigue 13 (6.2) 10 (6.4) 3 (5.7)
Vomiting 3 (1.4) 1 (0.6) 2 (3.8)
Colangitis 3 (1.4) 3 (1.9) –
Neurotoxicity 3 (1.4) 1 (0.6) 2 (3.8)
Peripheral neuropathy 5 (2.4) 3 (1.9) 2 (3.8)
Alopecia 9 (4.3) 6 (3.8) 3 (5.7)
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notably Da Vitta et al. (9.2 months). Of note, patients
of our cohort had poorer PS than that reported in
these studies.
As reported in previous studies, neutropenia was
the most common treatment-related adverse event of
grade 3 or higher, however its 18% incidence was
substantially below that reported in the MPACT trial
(38%) [9] and slightly lower than in previous series of
real-life patients (20 to 24%) [14, 19, 20]. Remarkably,
being aged over 70 years was not associated with a
worse toxicity profile in our study, consistent with
the trend reported by Giordano et al. in a retrospect-
ive study addressing the safety of this treatment in
the elderly [14].
Fig. 1 Overall survival (a, c and e) and progression-free survival (b, d and f) depending on baseline ECOG (a and b), NLR (c and d) and CA 19.9 (e
and f). Survival is presented as median (95% CI); p-values correspond to the Log-rank test for inter-curve differences
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In addition to assessing the safety and effectiveness of
first-line nab-paclitaxel plus gemcitabine in real-life
patients, we also analyzed prognostic factors and their
influence on survival in this setting. The influence of the
patient’s performance status has been consistently
reported by various authors. [18, 19, 21, 22] As in
previous analyses of real-life patients, [19, 21] stratifying
patients according to the baseline ECOG score of 0–1
or > 1, shows an influence of ECOG on OS. Similarly,
the inflammation-based NLR score, identified as a prog-
nostic factor for OS and PFS in patients receiving
nab-paclitaxel plus gemcitabine in pivotal studies [18]
Fig. 2 Overall survival (a, c and e) and progression-free survival (b, d and f) depending on baseline age (a and b), presence of hepatobiliary stent
(c and d), and relative dose intensity (RDI) (e and f). Survival is presented as median (95% CI); p-values correspond to the Log-rank test for
inter-curve differences
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and real-life practice [20, 21, 23], influenced OS in our
patients but did not reach the significance threshold in
the PFS analysis. In both localized and metastatic pan-
creatic adenocarcinoma, a proinflammatory status of the
tumor results in worse prognosis, and therefore, influ-
ences treatment response and consequently, survival. Fi-
nally, the antigen CA 19.9 significantly influenced both
OS and PFS with a cut-off of 37 U/mL. Other factors,
such as age, the presence of a hepatobiliary stent, and
the RDI did not significantly influence either OS or PFS.
This finding is particularly controversial for age, which
has been identified as a major prognostic factor for all
patients with metastatic pancreatic cancer [22], and was
subsequently confirmed for patients treated specifically
Fig. 3 Survival estimate of patients with metastatic pancreatic cancer starting combined treatment with nab-paclitaxel plus gemcitabine in
real-life practice. a Nomogram for predicting overall survival and the probability of 3-month, 6-month, 12-month in real-life practice. b Survival
(Kaplan Meier estimate) for low-, medium-, and high-risk groups
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with gemcitabine plus nab-paclitaxel [18]. It is worth
noting that the cut-off age considered as a prognostic
factor is not homogeneous across studies, and while risk
analyses were traditionally based on patients over 60 or
65 years [18, 22], there is increasing interest in investi-
gating patients over 70 years as a risk group in real-life
practice [14, 24].
The prognostic factors identified in our cohort (i.e.,
ECOG PF, NLR, and CA 19.9) allowed us to develop a
nomogram for predicting survival of real-life patients
treated with first-line nab-paclitaxel plus gemcitabine. A
similar tool for predicting survival in real-life patients
receiving gemcitabine-based chemotherapy was presented
by Hamada et al., and included age, sex, PS, tumor size,
and the presence of nodal or distant metastases [25]. As in
their analysis, PS carried a notable weight in our nomo-
gram, with patients having an ECOG score of 2 or more
dramatically reducing the predicted survival. On the other
hand, variables not routinely assessed in standard practice,
such as tumor size were not considered. In addition to the
nomogram by Hamada et al., Goldstein et al. presented a
similar tool based on the cohort of the MPACT trial [26].
The nomogram by Goldstein et al. was similar to ours in
terms of the inclusion of performance status and NLR, but
included other variables such as albumin, tumor size, and
the presence of liver metastasis. Future studies shall validate
the proposed nomogram as a tool for predicting survival in
real-life patients.
Our results should be interpreted in the context of the
intrinsic limitations of retrospective studies. Thus, in
addition to the risk of reporting bias associated with ob-
servational designs, missing data in the medical records
could not be considered for the analysis, leading uneven
sample sizes across analyses. The retrospective design
also precluded the inclusion of variables not recorded in
routine clinical practice in Spain, notably the Karnofsky
index, which was reported in very few patients and pre-
vented a direct comparison with the study sample of the
pivotal trial MPACT. Another limitation of the retro-
spective design was the lack of pre-defined criteria for
dose reductions, which were established at physician’s
discretion, according to the routine practice in each
center. Finally, the reduced size of some patient sub-
groups in the comparative analyses limited the investiga-
tion of baseline factors with potential influence on
patient survival.
Conclusions
Our results, obtained from the largest published series
of real-world patients with metastatic pancreatic cancer,
show that nab-paclitaxel plus gemcitabine remains
effective in this setting, despite the high burden of dose
reductions and the poorer performance of these patients.
Based on the exploratory analysis of prognostic factors,
a nomogram was developed to predict survival of
patients starting treatment with the combination. It was
based on three variables routinely assessed in real-life
practice, ECOG performance status, NLR, and CA 19.9.
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